Published in J Virol on October 10, 2007
Emerging concepts in the immunopathogenesis of AIDS. Annu Rev Med (2009) 3.94
Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers. AIDS (2009) 2.53
Mucosal immune responses to HIV-1 in elite controllers: a potential correlate of immune control. Blood (2008) 2.30
The Thai phase III trial (RV144) vaccine regimen induces T cell responses that preferentially target epitopes within the V2 region of HIV-1 envelope. J Immunol (2012) 1.75
Immune activation promotes evolutionary conservation of T-cell epitopes in HIV-1. PLoS Biol (2013) 1.44
A low T regulatory cell response may contribute to both viral control and generalized immune activation in HIV controllers. PLoS One (2011) 1.43
HIV controllers with HLA-DRB1*13 and HLA-DQB1*06 alleles have strong, polyfunctional mucosal CD4+ T-cell responses. J Virol (2010) 1.29
Effector mechanisms in HIV-1 infected elite controllers: highly active immune responses? Antiviral Res (2009) 1.25
Expression profile of host restriction factors in HIV-1 elite controllers. Retrovirology (2013) 1.24
T cell immunity in acute HIV-1 infection. J Infect Dis (2010) 1.22
Generalized immune activation as a direct result of activated CD4+ T cell killing. J Biol (2009) 1.22
HIV controller CD4+ T cells respond to minimal amounts of Gag antigen due to high TCR avidity. PLoS Pathog (2010) 1.17
HIV-specific CD4 T cells and immune control of viral replication. Curr Opin HIV AIDS (2011) 1.16
Plasmacytoid dendritic cells reduce HIV production in elite controllers. J Virol (2012) 1.09
In vivo blockade of the PD-1 receptor suppresses HIV-1 viral loads and improves CD4+ T cell levels in humanized mice. J Immunol (2012) 1.07
High antibody-dependent cellular cytotoxicity responses are correlated with strong CD8 T cell viral suppressive activity but not with B57 status in HIV-1 elite controllers. PLoS One (2013) 1.07
Human immunodeficiency virus vaccine trials. Cold Spring Harb Perspect Med (2012) 1.05
HIV controllers maintain a population of highly efficient Th1 effector cells in contrast to patients treated in the long term. J Virol (2012) 1.04
HIV-specific CD4+ T cells may contribute to viral persistence in HIV controllers. Clin Infect Dis (2011) 1.03
HIV controllers: a multifactorial phenotype of spontaneous viral suppression. Clin Immunol (2011) 1.02
Limited HIV infection of central memory and stem cell memory CD4+ T cells is associated with lack of progression in viremic individuals. PLoS Pathog (2014) 1.01
A DNA vaccine encoding multiple HIV CD4 epitopes elicits vigorous polyfunctional, long-lived CD4+ and CD8+ T cell responses. PLoS One (2011) 1.00
Increased CD4+ T cell levels during IL-7 administration of antiretroviral therapy-treated simian immunodeficiency virus-positive macaques are not dependent on strong proliferative responses. J Immunol (2010) 0.98
Targeting concatenated HIV antigens to human CD40 expands a broad repertoire of multifunctional CD4+ and CD8+ T cells. AIDS (2013) 0.96
Disease Progression in HIV-1-Infected Viremic Controllers. J Acquir Immune Defic Syndr (2012) 0.95
Differential Gag-specific polyfunctional T cell maturation patterns in HIV-1 elite controllers. J Virol (2012) 0.95
Genetically modified hematopoietic stem cell transplantation for HIV-1-infected patients: can we achieve a cure? Mol Ther (2013) 0.95
Long-term vaccine protection from AIDS and clearance of viral DNA following SHIV89.6P challenge. Vaccine (2009) 0.92
High CCR5 density on central memory CD4+ T cells in acute HIV-1 infection is mostly associated with rapid disease progression. PLoS One (2012) 0.92
Innate and Adaptive Immunity in Long-Term Non-Progression in HIV Disease. Front Immunol (2013) 0.91
An adjuvanted polyprotein HIV-1 vaccine induces polyfunctional cross-reactive CD4+ T cell responses in seronegative volunteers. Clin Infect Dis (2011) 0.91
Broadly-specific cytotoxic T cells targeting multiple HIV antigens are expanded from HIV+ patients: implications for immunotherapy. Mol Ther (2014) 0.91
Immune mechanisms of HIV control. Curr Opin Immunol (2010) 0.89
Thirty Years with HIV Infection-Nonprogression Is Still Puzzling: Lessons to Be Learned from Controllers and Long-Term Nonprogressors. AIDS Res Treat (2012) 0.86
Stable Phenotypic Changes of the Host T Cells Are Essential to the Long-Term Stability of Latent HIV-1 Infection. J Virol (2015) 0.85
CD4+ T-cell help enhances NK cell function following therapeutic HIV-1 vaccination. J Virol (2014) 0.85
Treatment with anti-FasL antibody preserves memory lymphocytes and virus-specific cellular immunity in macaques challenged with simian immunodeficiency virus. Blood (2009) 0.84
Robust immunity to an auxotrophic Mycobacterium bovis BCG-VLP prime-boost HIV vaccine candidate in a nonhuman primate model. J Virol (2013) 0.83
Immune responses during spontaneous control of HIV and AIDS: what is the hope for a cure? Philos Trans R Soc Lond B Biol Sci (2014) 0.81
Sang Froid in a time of trouble: is a vaccine against HIV possible? J Int AIDS Soc (2009) 0.81
CD4 T cell depletion at the cervix during HIV infection is associated with accumulation of terminally differentiated T cells. J Virol (2011) 0.80
Cell-Mediated Immunity in Elite Controllers Naturally Controlling HIV Viral Load. Front Immunol (2013) 0.80
Human immunodeficiency virus type I-specific CD8+ T cell subset abnormalities in chronic infection persist through effective antiretroviral therapy. BMC Infect Dis (2010) 0.80
Anti-APOBEC3G activity of HIV-1 Vif protein is attenuated in elite controllers. J Virol (2015) 0.79
Heterologous prime-boost regimens with a recombinant chimpanzee adenoviral vector and adjuvanted F4 protein elicit polyfunctional HIV-1-specific T-Cell responses in macaques. PLoS One (2015) 0.78
Immunogenicity and safety of a booster dose of an investigational adjuvanted polyprotein HIV-1 vaccine in healthy adults and effect of administration of chloroquine. Clin Vaccine Immunol (2014) 0.78
Public T cell receptors confer high-avidity CD4 responses to HIV controllers. J Clin Invest (2016) 0.78
Dendritic Cell Immune Responses in HIV-1 Controllers. Curr HIV/AIDS Rep (2017) 0.78
Different immunological phenotypes associated with preserved CD4+ T cell counts in HIV-infected controllers and viremic long term non-progressors. PLoS One (2013) 0.77
Characteristics of plasmacytoid dendritic cell and CD4+ T cell in HIV elite controllers. Clin Dev Immunol (2012) 0.77
The enduring tale of T cells in HIV immunopathogenesis. Indian J Med Res (2013) 0.77
Increased Levels of Macrophage Inflammatory Proteins Result in Resistance to R5-Tropic HIV-1 in a Subset of Elite Controllers. J Virol (2015) 0.77
A Chimeric HIV-1 gp120 Fused with Vaccinia Virus 14K (A27) Protein as an HIV Immunogen. PLoS One (2015) 0.77
The number of CCR5 expressing CD4+ T lymphocytes is lower in HIV-infected long-term non-progressors with viral control compared to normal progressors: a cross-sectional study. BMC Infect Dis (2014) 0.77
Recent developments in clinical trial designs for HIV vaccine research. Hum Vaccin Immunother (2015) 0.77
CD38 Expression in a Subset of Memory T Cells Is Independent of Cell Cycling as a Correlate of HIV Disease Progression. Dis Markers (2016) 0.77
DNA-MVA-protein vaccination of rhesus macaques induces HIV-specific immunity in mucosal-associated lymph nodes and functional antibodies. Vaccine (2017) 0.75
A transcriptome-based model of central memory CD4 T cell death in HIV infection. BMC Genomics (2016) 0.75
Dendritic Cell Targeting Effectively Boosts T Cell Responses Elicited by an HIV Multiepitope DNA Vaccine. Front Immunol (2017) 0.75
Low antigen-specific CD4 T-cell immune responses despite normal absolute CD4 counts after long-term antiretroviral therapy an African cohort. Immunol Lett (2014) 0.75
Higher Frequency of NK and CD4+ T-Cells in Mucosa and Potent Cytotoxic Response in HIV Controllers. PLoS One (2015) 0.75
A Subset of Extreme Human Immunodeficiency Virus (HIV) Controllers Is Characterized by a Small HIV Blood Reservoir and a Weak T-Cell Activation Level. Open Forum Infect Dis (2017) 0.75
DNA Vaccination by Electroporation Amplifies Broadly Cross-Restricted Public TCR Clonotypes Shared with HIV Controllers. J Immunol (2017) 0.75
Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med (2006) 24.38
HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood (2006) 17.38
The influence of CCL3L1 gene-containing segmental duplications on HIV-1/AIDS susceptibility. Science (2005) 17.00
Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science (1997) 15.09
Massive infection and loss of memory CD4+ T cells in multiple tissues during acute SIV infection. Nature (2005) 13.15
HIV-specific CD8+ T cell proliferation is coupled to perforin expression and is maintained in nonprogressors. Nat Immunol (2002) 10.37
Genomic structure of an attenuated quasi species of HIV-1 from a blood transfusion donor and recipients. Science (1995) 10.02
Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J Infect Dis (1999) 9.81
HIV preferentially infects HIV-specific CD4+ T cells. Nature (2002) 9.28
Brief report: absence of intact nef sequences in a long-term survivor with nonprogressive HIV-1 infection. N Engl J Med (1995) 8.15
HIV-1-specific CD4+ T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression. Nat Med (1999) 7.77
CD69 acts downstream of interferon-alpha/beta to inhibit S1P1 and lymphocyte egress from lymphoid organs. Nature (2006) 7.17
Correlates of immune protection in HIV-1 infection: what we know, what we don't know, what we should know. Nat Med (2004) 5.49
HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype. Proc Natl Acad Sci U S A (2007) 4.96
Maintenance of viral suppression in HIV-1-infected HLA-B*57+ elite suppressors despite CTL escape mutations. J Exp Med (2006) 4.62
Quantification of CD4, CCR5, and CXCR4 levels on lymphocyte subsets, dendritic cells, and differentially conditioned monocyte-derived macrophages. Proc Natl Acad Sci U S A (1999) 4.61
HIV-1 viremia prevents the establishment of interleukin 2-producing HIV-specific memory CD4+ T cells endowed with proliferative capacity. J Exp Med (2003) 4.53
Isolation and characterization of replication-competent human immunodeficiency virus type 1 from a subset of elite suppressors. J Virol (2006) 4.27
Chemokine receptor CCR7 required for T lymphocyte exit from peripheral tissues. Nat Immunol (2005) 4.26
Pathogenesis of HIV infection: what the virus spares is as important as what it destroys. Nat Med (2006) 4.23
HLA Alleles Associated with Delayed Progression to AIDS Contribute Strongly to the Initial CD8(+) T Cell Response against HIV-1. PLoS Med (2006) 4.19
HIV controllers: a homogeneous group of HIV-1-infected patients with spontaneous control of viral replication. Clin Infect Dis (2005) 3.77
Progressive CD4+ central memory T cell decline results in CD4+ effector memory insufficiency and overt disease in chronic SIV infection. J Exp Med (2007) 3.45
Acquisition of direct antiviral effector functions by CMV-specific CD4+ T lymphocytes with cellular maturation. J Exp Med (2006) 3.26
Understanding the generation and function of memory T cell subsets. Curr Opin Immunol (2005) 3.22
Functional heterogeneity of memory CD4 T cell responses in different conditions of antigen exposure and persistence. J Immunol (2005) 3.04
Presence of HIV-1 Gag-specific IFN-gamma+IL-2+ and CD28+IL-2+ CD4 T cell responses is associated with nonprogression in HIV-1 infection. J Immunol (2002) 2.95
Cooperation between CD4+ and CD8+ T cells: when, where, and how. Annu Rev Immunol (2006) 2.71
The role of programming in memory T-cell development. Curr Opin Immunol (2004) 2.41
Chemokine receptor expression identifies Pre-T helper (Th)1, Pre-Th2, and nonpolarized cells among human CD4+ central memory T cells. J Exp Med (2004) 2.38
High-level HIV-1 viremia suppresses viral antigen-specific CD4(+) T cell proliferation. Proc Natl Acad Sci U S A (2001) 2.32
Beta-chemokines are released from HIV-1-specific cytolytic T-cell granules complexed to proteoglycans. Nature (1998) 2.30
Effects of in vivo CD8(+) T cell depletion on virus replication in rhesus macaques immunized with a live, attenuated simian immunodeficiency virus vaccine. J Exp Med (2000) 2.10
Interleukin-2 enhances CD4+ T cell memory by promoting the generation of IL-7R alpha-expressing cells. J Exp Med (2007) 1.99
The impact of CCR7 and CXCR5 on lymphoid organ development and systemic immunity. Immunol Rev (2003) 1.79
Loss of CD4+ T cell proliferative ability but not loss of human immunodeficiency virus type 1 specificity equates with progression to disease. J Infect Dis (2000) 1.66
Differentiation of memory B and T cells. Curr Opin Immunol (2006) 1.59
Chemokine receptor internalization and intracellular trafficking. Cytokine Growth Factor Rev (2005) 1.59
Induction of a virus-specific effector-memory CD4+ T cell response by attenuated SIV infection. J Exp Med (2006) 1.55
Replication-competent HIV strains infect HIV controllers despite undetectable viremia (ANRS EP36 study). AIDS (2007) 1.53
Fully differentiated HIV-1 specific CD8+ T effector cells are more frequently detectable in controlled than in progressive HIV-1 infection. PLoS One (2007) 1.52
Identification of circulating antigen-specific CD4+ T lymphocytes with a CCR5+, cytotoxic phenotype in an HIV-1 long-term nonprogressor and in CMV infection. Blood (2003) 1.44
Even individuals considered as long-term nonprogressors show biological signs of progression after 10 years of human immunodeficiency virus infection. Blood (1997) 1.40
HIV-1 natural viral suppressors: control of viral replication in the absence of therapy. AIDS (2007) 1.38
Combined effect of CCR5-Delta32 heterozygosity and the CCR5 promoter polymorphism -2459 A/G on CCR5 expression and resistance to human immunodeficiency virus type 1 transmission. J Virol (2005) 1.30
Genetics of resistance to HIV infection: Role of co-receptors and co-receptor ligands. Semin Immunol (2006) 1.24
HIV-induced immunopathogenesis. Immunity (1998) 1.19
Prognostic value of HIV-1 Gag-specific CD4+ T-cell responses for progression to AIDS analyzed in a prospective cohort study. Blood (2005) 1.19
The duration of exposure to HIV modulates the breadth and the magnitude of HIV-specific memory CD4+ T cells. J Immunol (2007) 1.18
CD4+ T cell responses in HIV-exposed seronegative women are qualitatively distinct from those in HIV-infected women. J Infect Dis (2004) 1.09
HIV-specific CD4+ T cells and viremia: who's in control? Trends Immunol (2006) 0.96
HIV-infected long-term nonprogressors: epidemiology, mechanisms of delayed progression, and clinical and research implications. Microbes Infect (1999) 0.94
Functional patterns of HIV-1-specific CD4 T-cell responses in children are influenced by the extent of virus suppression and exposure. AIDS (2007) 0.94
Status of long-term asymptomatic HIV-1 infection correlates with viral load but not with virus replication properties and cell tropism. French ALT Study Group. J Med Virol (1999) 0.88
Presence of HIV-specific CD4+ T-cell responses in HIV-infected subjects with sustained virologic control after highly active antiretroviral therapy. J Acquir Immune Defic Syndr (2004) 0.81
Immune-based therapy for HIV infection: are acute and chronic HIV infection different diseases? J Infect Dis (2006) 0.81
Loss of HIV-1-specific T cell proliferation in chronic HIV-1 infection: cause or consequence of viral replication? AIDS (2005) 0.79
Interleukin-4 promotes human CD8 T cell expression of CCR7. Immunology (2006) 0.78
Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med (2006) 24.38
Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med (2011) 7.13
Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study. PLoS Pathog (2013) 6.14
Changes in the risk of death after HIV seroconversion compared with mortality in the general population. JAMA (2008) 6.07
HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype. Proc Natl Acad Sci U S A (2007) 4.96
On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection. N Engl J Med (2015) 4.26
Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med (2003) 4.19
HIV controllers: a homogeneous group of HIV-1-infected patients with spontaneous control of viral replication. Clin Infect Dis (2005) 3.77
Enhanced T cell recovery in HIV-1-infected adults through IL-7 treatment. J Clin Invest (2009) 2.92
Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry. Arthritis Rheum (2010) 2.68
Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV. J Acquir Immune Defic Syndr (2004) 2.55
Genomewide association study of an AIDS-nonprogression cohort emphasizes the role played by HLA genes (ANRS Genomewide Association Study 02). J Infect Dis (2009) 2.53
Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers. AIDS (2009) 2.53
Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome. Arthritis Rheumatol (2014) 2.40
Critical role of JC virus-specific CD4 T-cell responses in preventing progressive multifocal leukoencephalopathy. AIDS (2003) 2.30
Synergistic activation of HIV-1 expression by deacetylase inhibitors and prostratin: implications for treatment of latent infection. PLoS One (2009) 2.23
Prolonged valproic acid treatment does not reduce the size of latent HIV reservoir. AIDS (2008) 2.21
Heterogeneity in HIV suppression by CD8 T cells from HIV controllers: association with Gag-specific CD8 T cell responses. J Immunol (2009) 2.17
Distinct genetic loci control plasma HIV-RNA and cellular HIV-DNA levels in HIV-1 infection: the ANRS Genome Wide Association 01 study. PLoS One (2008) 2.14
Prevalence of HIV-related pulmonary arterial hypertension in the current antiretroviral therapy era. Am J Respir Crit Care Med (2007) 2.03
CD4 cell count and HIV DNA level are independent predictors of disease progression after primary HIV type 1 infection in untreated patients. Clin Infect Dis (2006) 2.02
CD8+ T cells specific for EBV, cytomegalovirus, and influenza virus are activated during primary HIV infection. J Immunol (2004) 1.93
Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials. J Acquir Immune Defic Syndr (2005) 1.87
Spread of hepatitis C virus among European injection drug users infected with HIV: a phylogenetic analysis. J Infect Dis (2004) 1.85
Changes over calendar time in the risk of specific first AIDS-defining events following HIV seroconversion, adjusting for competing risks. Int J Epidemiol (2002) 1.79
Positive outcomes of HAART at 24 months in HIV-infected patients in Cambodia. AIDS (2007) 1.77
Spontaneous control of viral load and CD4 cell count progression among HIV-1 seroconverters. AIDS (2005) 1.75
Idiopathic CD4+ T-cell lymphocytopenia is associated with impaired membrane expression of the chemokine receptor CXCR4. Blood (2009) 1.74
Distinctive NK-cell receptor repertoires sustain high-level constitutive NK-cell activation in HIV-exposed uninfected individuals. Blood (2007) 1.72
Romiplostim safety and efficacy for immune thrombocytopenia in clinical practice: 2-year results of 72 adults in a romiplostim compassionate-use program. Blood (2011) 1.71
Impact of a patient education program on adherence to HIV medication: a randomized clinical trial. J Acquir Immune Defic Syndr (2003) 1.69
The Shigella flexneri type three secretion system effector IpgD inhibits T cell migration by manipulating host phosphoinositide metabolism. Cell Host Microbe (2011) 1.66
Reduced CD4 T cell activation and in vitro susceptibility to HIV-1 infection in exposed uninfected Central Africans. Retrovirology (2006) 1.64
Undetectable viremia without antiretroviral therapy in patients with HIV seroconversion: an uncommon phenomenon? Clin Infect Dis (2005) 1.64
Early levels of HIV-1 DNA in peripheral blood mononuclear cells are predictive of disease progression independently of HIV-1 RNA levels and CD4+ T cell counts. J Infect Dis (2005) 1.64
Restriction of HIV-1 replication in macrophages and CD4+ T cells from HIV controllers. Blood (2011) 1.62
Sustained control of viremia following therapeutic immunization in chronically HIV-1-infected individuals. AIDS (2006) 1.61
HIV controllers: how do they tame the virus? Trends Immunol (2007) 1.61
Genomewide association study of a rapid progression cohort identifies new susceptibility alleles for AIDS (ANRS Genomewide Association Study 03). J Infect Dis (2009) 1.57
Comparing the public health burden of chronic hepatitis C and HIV infection in France. J Hepatol (2004) 1.57
Acquired hemophilia in older people: a poor prognosis despite intensive care. J Am Geriatr Soc (2007) 1.54
Type I interferon production is profoundly and transiently impaired in primary HIV-1 infection. J Infect Dis (2005) 1.54
Replication-competent HIV strains infect HIV controllers despite undetectable viremia (ANRS EP36 study). AIDS (2007) 1.53
The lymphocyte HIV reservoir in patients on long-term HAART is a memory of virus evolution. AIDS (2004) 1.52
The enteropathy associated with common variable immunodeficiency: the delineated frontiers with celiac disease. Am J Gastroenterol (2010) 1.50
Safety of enfuvirtide in combination with an optimized background of antiretrovirals in treatment-experienced HIV-1-infected adults over 48 weeks. J Acquir Immune Defic Syndr (2005) 1.50
Interleukin-2 before antiretroviral therapy in patients with HIV infection: a randomized trial (ANRS 119). J Infect Dis (2009) 1.49
Old age and anti-cytomegalovirus immunity are associated with altered T-cell reconstitution in HIV-1-infected patients. AIDS (2011) 1.47
Is the level of proof of the North American multicohort collaboration prospective study sufficient to conclude that incidence of invasive cervical cancer is higher in HIV-infected women? J Acquir Immune Defic Syndr (2013) 1.42
A molecular basis for the control of preimmune escape variants by HIV-specific CD8+ T cells. Immunity (2013) 1.41
Characteristics and long-term outcome of 15 episodes of systemic lupus erythematosus-associated hemophagocytic syndrome. Medicine (Baltimore) (2006) 1.41
Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med (2004) 1.40
Escape from highly effective public CD8+ T-cell clonotypes by HIV. Blood (2011) 1.39
Acute plasma biomarkers of T cell activation set-point levels and of disease progression in HIV-1 infection. PLoS One (2012) 1.39
Histone methyltransferase inhibitors induce HIV-1 recovery in resting CD4(+) T cells from HIV-1-infected HAART-treated patients. AIDS (2012) 1.38
A survey of 90 patients with autoimmune lymphoproliferative syndrome related to TNFRSF6 mutation. Blood (2011) 1.36
Epidemiology and clinical characteristics of elite controllers. Curr Opin HIV AIDS (2011) 1.35
Spontaneous control of viral replication during primary HIV infection: when is "HIV controller" status established? Clin Infect Dis (2009) 1.35
Adherence to antiretroviral therapy in patients enrolled in a comprehensive care program in Cambodia: a 24-month follow-up assessment. Antivir Ther (2008) 1.35
Association study of common genetic variants and HIV-1 acquisition in 6,300 infected cases and 7,200 controls. PLoS Pathog (2013) 1.33
Does transient HAART during primary HIV-1 infection lower the virological set-point? AIDS (2004) 1.31